D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 46.88 CNY -1.62% Market Closed
Market Cap: 19.5B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dizal Jiangsu Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison

Comparables:
6160
603392
002252
300122
300896

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Cost of Revenue
-ÂĄ3.2m
CAGR 3-Years
49%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cost of Revenue
-ÂĄ2.7B
CAGR 3-Years
-77%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cost of Revenue
-ÂĄ992.7m
CAGR 3-Years
-28%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cost of Revenue
-ÂĄ5B
CAGR 3-Years
-54%
CAGR 5-Years
-46%
CAGR 10-Years
-33%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cost of Revenue
-ÂĄ35.1B
CAGR 3-Years
-49%
CAGR 5-Years
-51%
CAGR 10-Years
-62%
Imeik Technology Development Co Ltd
SZSE:300896
Cost of Revenue
-ÂĄ140.8m
CAGR 3-Years
-36%
CAGR 5-Years
-32%
CAGR 10-Years
N/A

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-3.2m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Cost of Revenue amounts to -3.2m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
38%

The average annual Cost of Revenue growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 49% over the past three years , 38% over the past five years .

Back to Top